GRTX Share Price | Galera Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Galera Therapeutics, Inc.?

Market Cap: As of Jun 18, Galera Therapeutics, Inc. has a market capitalization of 2.12 million, classifying it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, the company reported net sales of 0.00 million and a net profit of -16.16 million.Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds were -143.67 million, and total assets amounted to 10.10 million.

Q: What does Galera Therapeutics, Inc. do?

Overview: Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics to transform radiotherapy in cancer, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 2.12 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.00 Return on Equity: 7.56% Price to Book: -0.01Contact Details: Address: 2 W Liberty Blvd Ste 100, MALVERN PA: 19355-1435 Tel: 1 610 7251500 Fax: 1 302 6365454 Website: https://www.galeratx.com/

Q: Is Galera Therapeutics, Inc. technically bullish or bearish?

As of 18 March 2025, the technical trend for Galera Therapeutics, Inc. has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly and monthly MACD readings are mildly bullish. However, the KST is bearish on both weekly and monthly time frames, and there is no trend indicated by Dow Theory or OBV. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple time frames, with a 1-year return of -74.84% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and bearish KST indicators.

Results Declared: Galera Therapeutics, Inc. has declared results on 19 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

413.4 k

Shareholding (Dec 2025)

FII

5.78%

Held by 8 FIIs

DII

91.11%

Held by 3 DIIs

Promoter

0.81%

How big is Galera Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Galera Therapeutics, Inc. has a market capitalization of 2.12 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -16.16 million for the latest four quarters ending in March 2025. As of December 2024, the company's shareholder's funds were -143.67 million, and total assets amounted to 10.10 million.

View full answer

What does Galera Therapeutics, Inc. do?

22-Jun-2025

Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics to enhance cancer radiotherapy. It has a market cap of $2.12 million and reported a net profit loss of $2 million as of March 2025.

View full answer

Who are in the management team of Galera Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Galera Therapeutics, Inc. includes Dr. Michael Powell (Independent Chairman), Dr. J. Mel Sorensen (President and CEO), Dr. Emmett Cunningham, and independent directors Mr. Lawrence Alleva, Mr. Kevin Lokay, and Ms. Linda West. They oversee the company's strategic direction and operations.

View full answer

Is Galera Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of March 18, 2025, Galera Therapeutics, Inc. shows a mildly bearish trend due to daily moving averages and bearish KST indicators, significantly underperforming the S&P 500 with a 1-year return of -74.84%.

View full answer

Compare Galera Therapeutics, Inc. with Similar Stocks

Protagenic Therapeutics, Inc.Oragenics, Inc.Lexaria Bioscience Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.00

Return on Equity

4.02%

Price to Book

-0.02

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

153 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

81.47%

6 Months

168.57%

1 Year

37.83%

2 Years

-79.91%

3 Years

-97.86%

4 Years

-98.16%

5 Years

-99.55%

Galera Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

13.81%

EBIT to Interest (avg)

-8.59

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

Tax Ratio

1.24%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.38%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.02

EV to EBIT

-24.40

EV to EBITDA

-24.40

EV to Capital Employed

-150.22

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bullish

Sideways

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (2.3%)

Foreign Institutions

Held by 8 Foreign Institutions (5.78%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 3,224.49% vs 12.50% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.50",
          "val2": "-1.60",
          "chgp": "6.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "154.50",
          "val2": "-3.40",
          "chgp": "4,644.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "153.10",
          "val2": "-4.90",
          "chgp": "3,224.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 884.21% vs 67.85% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.00",
          "val2": "-14.10",
          "chgp": "57.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "154.80",
          "val2": "-5.60",
          "chgp": "2,864.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "149.00",
          "val2": "-19.00",
          "chgp": "884.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.50

-1.60

6.25%

Interest

0.00

Exceptional Items

154.50

-3.40

4,644.12%

Consolidate Net Profit

153.10

-4.90

3,224.49%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 3,224.49% vs 12.50% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.00

-14.10

57.45%

Interest

0.00

Exceptional Items

154.80

-5.60

2,864.29%

Consolidate Net Profit

149.00

-19.00

884.21%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 884.21% vs 67.85% in Dec 2024

All Annual Results

Company CV

About Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Galera Therapeutics, Inc is a clinical stage biopharmaceutical company. It is focused on developing and commercializing a pipeline therapeutics to transform radiotherapy in cancer. It is focused on leveraging capability in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy. Its pipeline product are GC4419 and GC4711. Its lead product candidate GC4419, is a potent selective small molecule dismutase mimetic. The Company is initially focused on developing GC4419 for the reduction of severe oral mucositis (SOM). GC4419, is also known as avasopasem manganese, and has completed two clinical trials. The Company’s second dismutase mimetic product candidate is GC4711. The Company is specifically targeting GC4711, an analog of GC4419, to increase the anti-cancer efficacy of SBRT. It is in Phase 1 development both as a lyophilized product for intravenous administration given as an oral capsule.

Company Coordinates

Company Details

2 W Liberty Blvd Ste 100 , MALVERN PA : 19355-1435

Tel: 1 610 7251500

https://www.galeratx.com/

Registrar Details